23
Participants
Start Date
October 24, 2018
Primary Completion Date
October 10, 2022
Study Completion Date
October 10, 2022
Carfilzomib
Given IV
Dexamethasone
Given IV
Nivolumab
Given IV
Pelareorep
Given IV
Emory University Hospital/Winship Cancer Institute, Atlanta
Huntsman Cancer Institute/University of Utah, Salt Lake City
Collaborators (3)
Bristol-Myers Squibb
INDUSTRY
Oncolytics Biotech
INDUSTRY
University of Utah
OTHER
City of Hope Medical Center
OTHER
Phylogeny
UNKNOWN
National Cancer Institute (NCI)
NIH
National Institutes of Health (NIH)
NIH
Emory University
OTHER